Alexandra Bouvard1, Maud Dupuy2, Pierre Schweitzer2, Mathieu Revranche2, Melina Fatseas3, Fuschia Serre3, David Misdrahi2,4, Marc Auriacombe3, Joel Swendsen2,5. 1. University Paris-Sud, Orsay, France. 2. University of Bordeaux, CNRS-UMR 5287-Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (INCIA), Bordeaux, France. 3. Addiction Psychiatry Team, SANPsy CNRS USR 3413, Pôle Addictologie, CH Charles Perrens and CHU de Bordeaux, Bordeaux, France. 4. Pole de Psychiatrie 347, C.H. Charles Perrens, Bordeaux cedex, France. 5. EPHE, PSL Research University, Paris, France.
Abstract
BACKGROUND AND OBJECTIVES: Mobile testing of executive deficits in substance-related addictions is highly novel but requires validation. METHODS: Sixty-one individuals (34 patients, 27 healthy controls) completed Ecological Momentary Assessments with mobile executive tests. RESULTS: Compliance with the tests was high (78% to 91%) in both the patient and control groups. No fatigue effects were detected, practice effects were observed for controls only, and convergent validity was found relative to neuropsychological assessments. Conclusions The use of mobile cognitive testing is feasible and valid in this population. Scientific Significance Mobile cognitive tests provide new opportunities for both research and clinical intervention. (Am J Addict 2018;27:553-556).
BACKGROUND AND OBJECTIVES: Mobile testing of executive deficits in substance-related addictions is highly novel but requires validation. METHODS: Sixty-one individuals (34 patients, 27 healthy controls) completed Ecological Momentary Assessments with mobile executive tests. RESULTS: Compliance with the tests was high (78% to 91%) in both the patient and control groups. No fatigue effects were detected, practice effects were observed for controls only, and convergent validity was found relative to neuropsychological assessments. Conclusions The use of mobile cognitive testing is feasible and valid in this population. Scientific Significance Mobile cognitive tests provide new opportunities for both research and clinical intervention. (Am J Addict 2018;27:553-556).
Authors: Jessica A Bomyea; Emma M Parrish; Emily W Paolillo; Tess F Filip; Lisa T Eyler; Colin A Depp; Raeanne C Moore Journal: J Clin Exp Neuropsychol Date: 2021-09-08 Impact factor: 2.283
Authors: Raeanne C Moore; Laura M Campbell; Jeremy D Delgadillo; Emily W Paolillo; Erin E Sundermann; Jason Holden; Pierre Schweitzer; Robert K Heaton; Joel Swendsen Journal: Arch Clin Neuropsychol Date: 2020-05-22 Impact factor: 2.813
Authors: Antonio Verdejo-Garcia; Valentina Lorenzetti; Victoria Manning; Hugh Piercy; Raimondo Bruno; Rob Hester; David Pennington; Serenella Tolomeo; Shalini Arunogiri; Marsha E Bates; Henrietta Bowden-Jones; Salvatore Campanella; Stacey B Daughters; Christos Kouimtsidis; Dan I Lubman; Dieter J Meyerhoff; Annaketurah Ralph; Tara Rezapour; Hosna Tavakoli; Mehran Zare-Bidoky; Anna Zilverstand; Douglas Steele; Scott J Moeller; Martin Paulus; Alex Baldacchino; Hamed Ekhtiari Journal: Front Psychiatry Date: 2019-12-23 Impact factor: 4.157